Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label multicenter Phase 2 trial of eculizumab in STEC-HUS
2011-002691-17Phase 2Completed
- Sponsor
- Alexion Pharmaceuticals
- Start
- Jun 2011
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of eculizumab in hemolytic uremic syndrome (HUS), sponsored by Alexion Pharmaceuticals. Primary endpoint: Efficacy. Started Jun 2011; status: completed.
02
Drugs
eculizumab
03
Conditions
hemolytic uremic syndrome (HUS)
Beyond the preview
Go deeper on 2011-002691-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-002691-17.